NYSE:TFX • US8793691069
The current stock price of TFX is 122.06 USD. In the past month the price increased by 15.72%. In the past year, price decreased by -8.05%.
ChartMill assigns a technical rating of 3 / 10 to TFX. When comparing the yearly performance of all stocks, TFX is a bad performer in the overall market: 66.41% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to TFX. TFX has an average financial health and profitability rating.
Over the last trailing twelve months TFX reported a non-GAAP Earnings per Share(EPS) of 12.24. The EPS decreased by -12.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.17% | ||
| ROE | -8.58% | ||
| Debt/Equity | 0.67 |
18 analysts have analysed TFX and the average price target is 137.93 USD. This implies a price increase of 13% is expected in the next year compared to the current price of 122.06.
For the next year, analysts expect an EPS growth of 18.37% and a revenue growth 10.52% for TFX
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 20.26 | 202.161B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.26 | 180.008B | ||
| SYK | STRYKER CORP | 25.62 | 147.637B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.94 | 112.339B | ||
| IDXX | IDEXX LABORATORIES INC | 44.32 | 52.758B | ||
| BDX | BECTON DICKINSON AND CO | 11.2 | 50.332B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.08 | 49.848B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.78 | 38.246B | ||
| RMD | RESMED INC | 20.87 | 37.448B | ||
| DXCM | DEXCOM INC | 29.08 | 29.01B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Teleflex, Inc. engages in the provision of medical technology products. The company is headquartered in Wayne, Pennsylvania and currently employs 14,100 full-time employees. The firm offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. The company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. The company operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike and TrapLiner catheters, Pulsar-18 T3 Self-Expanding 4F Stent and Orsiro Mission Drug Eluting Stent.
TELEFLEX INC
550 E Swedesford Rd, Suite 400
Wayne PENNSYLVANIA 19087 US
CEO: Liam J. Kelly
Employees: 14100
Phone: 16102256800
Teleflex, Inc. engages in the provision of medical technology products. The company is headquartered in Wayne, Pennsylvania and currently employs 14,100 full-time employees. The firm offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. The company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. The company operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike and TrapLiner catheters, Pulsar-18 T3 Self-Expanding 4F Stent and Orsiro Mission Drug Eluting Stent.
The current stock price of TFX is 122.06 USD. The price increased by 2.55% in the last trading session.
TELEFLEX INC (TFX) has a dividend yield of 1.14%. The yearly dividend amount is currently 1.36.
TFX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
18 analysts have analysed TFX and the average price target is 137.93 USD. This implies a price increase of 13% is expected in the next year compared to the current price of 122.06.
The Revenue of TELEFLEX INC (TFX) is expected to grow by 10.52% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
TELEFLEX INC (TFX) has a market capitalization of 5.39B USD. This makes TFX a Mid Cap stock.